Yes, methotrexate can cause tinnitus, but it is an uncommon and dose-dependent adverse effect rather than a typical one. The link is best documented at high-dose regimens used in oncology, where tinnitus appears in roughly 1 to 5 percent of patients and usually signals elevated serum drug levels. At the low weekly doses used for rheumatoid arthritis and psoriasis (7.5 to 25 mg), tinnitus is rare, reported in under 1 percent of users, and often reversible. The mechanism is not direct cochlear destruction but folate antagonism, purine starvation, and cumulative neurotoxicity affecting the auditory pathway. Anyone with new ringing on methotrexate should have levels checked and folate status reviewed before assuming the drug is innocent.
How Methotrexate Reaches the Inner Ear: The Mechanism
Methotrexate is a folate antagonist. It blocks dihydrofolate reductase, which starves rapidly dividing cells of thymidine and purines. That is why it works against cancer and autoimmune inflammation. The same biochemistry explains why it can irritate the auditory system.
The inner ear is metabolically hungry. The stria vascularis, the tissue that maintains the cochlear electrical gradient, turns over cells and depends on folate-dependent one-carbon metabolism. When methotrexate suppresses that pathway, the cochlea's potassium recycling can falter. The result is a subtle shift in hair cell function that patients perceive as ringing or a high-pitched hiss.
A second route runs through homocysteine. Methotrexate raises plasma homocysteine by blocking folate recycling. Elevated homocysteine is associated with microvascular endothelial dysfunction. In the cochlea, which has a fragile blood supply through the labyrinthine artery, that translates to reduced perfusion and oxidative stress. This is a hypothesized mechanism rather than a proven one, but it fits the observation that tinnitus on methotrexate often improves when folate is repleted.
A third mechanism is direct neurotoxicity at high serum concentrations. Methotrexate crosses the blood-brain barrier poorly at low doses but measurably at high doses, especially with impaired renal clearance. Auditory pathway neurons, like other central neurons, can show excitability changes when folate metabolism is disrupted. This is why high-dose hospital regimens monitor levels so closely.
In plain terms: methotrexate does not usually poison the ear directly. It disturbs the chemistry the ear depends on, and the ringing is a downstream signal of that disturbance.
How Common Is Tinnitus on Methotrexate? Quantified Context
Exact incidence is hard to pin down because tinnitus is self-reported and often dismissed. The best available figures come from oncology and rheumatology cohorts. Per FDA labeling and pooled oncology safety data, ototoxicity including tinnitus is listed among the less common adverse reactions at high-dose methotrexate, generally cited at 1 to 5 percent. In low-dose rheumatoid arthritis registries, tinnitus is reported in fewer than 1 in 100 patients, and many of those cases have alternative explanations such as salicylate co-therapy or age-related hearing loss.
| Setting | Typical weekly or cycle dose | Reported tinnitus incidence | Typical onset |
|---|---|---|---|
| Rheumatoid arthritis (oral) | 7.5 to 25 mg weekly | Under 1 percent | Weeks to months |
| Psoriasis (oral) | 7.5 to 25 mg weekly | Under 1 percent | Weeks to months |
| High-dose oncology (IV) | 1,000 to 12,000 mg per cycle | 1 to 5 percent | Hours to days |
| Intrathecal | 10 to 15 mg per dose | Rare, case reports | Days |
| Low-dose with folate supplement | 7.5 to 25 mg weekly | Not reliably distinguishable from baseline | — |
The contrast matters. A 25 mg weekly rheumatoid arthritis dose is roughly 1/50th to 1/500th of a high-dose oncology cycle. That 50- to 500-fold difference is the single best explanation for why tinnitus is a headline concern in cancer care and a footnote in rheumatology.
Timeline: When Tinnitus Appears and When It Fades
Tinnitus from methotrexate does not follow one clock. It depends on route, dose, kidney function, and folate status. The table below reconciles the typical patterns reported across case series and pharmacovigilance data. Note that these are ranges, not guarantees, and individual variation is wide.
| Timeframe | What typically happens | Clinical meaning |
|---|---|---|
| Within 24 to 72 hours of a high IV dose | Acute tinnitus, sometimes with vertigo or hearing muffling | Suggests peak serum level issue; check level and creatinine |
| 1 to 4 weeks into low-dose therapy | Gradual onset of mild ringing, often bilateral | Consider folate depletion or homocysteine rise |
| 2 to 8 weeks | Tinnitus may plateau or resolve if folate is repleted | Reversible phase; act before 8 weeks if possible |
| 3 to 6 months | Persistent tinnitus in a minority; usually stable | Evaluate for alternative causes before blaming drug |
| After dose reduction or discontinuation | Improvement in 50 to 70 percent of reversible cases within 4 to 12 weeks | Supports drug-related mechanism |
| Beyond 6 months off drug | Residual tinnitus suggests permanent change or another cause | Audiometry and ENT referral warranted |
The 8-week mark is a practical threshold. Tinnitus that persists beyond two months on a stable low dose is less likely to be purely drug-driven and more likely to involve age-related hearing loss, noise exposure, or a concomitant medication.
Low-Dose Versus High-Dose: A Real Comparison
Patients and clinicians conflate these two worlds constantly. They are pharmacologically distinct. The comparison below matters because the same drug name carries very different tinnitus risk depending on context.
| Feature | Low-dose (rheumatology, dermatology) | High-dose (oncology) |
|---|---|---|
| Dose range | 7.5 to 25 mg weekly | 1,000 to 12,000 mg per cycle |
| Route | Oral or subcutaneous | Intravenous, sometimes intrathecal |
| Folate supplementation | Routine (1 mg daily) | Leucovorin rescue |
| Tinnitus incidence | Under 1 percent | 1 to 5 percent |
| Primary mechanism | Folate depletion, homocysteine rise | Peak serum levels, renal clearance limits |
| Reversibility | High if caught early | Variable; depends on level and timing |
| Monitoring | CBC, liver, kidney every 3 to 6 months | Serum level at 24, 48, 72 hours |
The numbers reconcile cleanly: the risk scales with dose and with how quickly the drug clears. A patient with an eGFR of 45 mL/min on low-dose methotrexate may reach serum levels closer to a high-dose patient's trough, which is why kidney function is checked before every dose escalation.
Non-Obvious Details Most Articles Miss
The first surprise is that folate supplementation changes the tinnitus picture. Routine folic acid at 1 mg daily reduces methotrexate side effects overall and may blunt the homocysteine rise that plausibly drives cochlear irritation. Some case reports describe tinnitus resolving within weeks of adding folate without changing the methotrexate dose.
The second is the salicylate trap. Many rheumatoid arthritis patients take NSAIDs or aspirin alongside methotrexate. Salicylates themselves cause tinnitus, and they also reduce renal methotrexate clearance by competing for tubular secretion. A patient with new ringing on both drugs may be experiencing a drug interaction, not methotrexate alone. This is a corrected misconception worth stating plainly: not every new tinnitus on methotrexate is caused by methotrexate.
The third is that intrathecal methotrexate, though a tiny dose (10 to 15 mg), has been linked to rare cases of tinnitus and hearing loss because it bathes the cerebrospinal fluid directly. Route matters as much as milligrams.
The fourth is the folate paradox. Methotrexate is a folate antagonist, but folate deficiency itself is associated with tinnitus through homocysteine elevation. So a patient can be both folate-deficient and methotrexate-treated, and the two effects compound rather than cancel.
Red Flags: When Tinnitus Is Not Just Tinnitus
Most ringing on methotrexate is benign and reversible. Some presentations require urgent action. The list below is the safety checklist every prescriber should run through.
- Sudden one-sided tinnitus with hearing loss within 72 hours: treat as a medical emergency, because sudden sensorineural hearing loss has a narrow treatment window.
- Tinnitus with vertigo, vomiting, or gait instability: suggests vestibular involvement and possible high serum levels.
- Ringing accompanied by mouth ulcers, fever, or bruising: possible methotrexate toxicity, which can escalate to pancytopenia.
- Tinnitus with decreased urine output or swelling: suspect acute kidney injury reducing drug clearance.
- New ringing in a patient who missed recent blood work: check CBC, creatinine, and liver enzymes before the next dose.
- Tinnitus plus confusion or seizures at high dose: possible acute neurotoxicity requiring level measurement and leucovorin.
What to Actually Do: Practical Actions
If you develop ringing while on methotrexate, the first step is not to stop the drug on your own. Abrupt cessation of a disease-modifying drug can flare arthritis or psoriasis. Instead, document the pattern: onset date, whether it is one-sided or both-sided, whether it pulses, and whether it worsens after each dose.
Next, request blood work. A complete blood count, creatinine with eGFR, liver panel, and serum methotrexate level (if within 72 hours of a high dose) will separate drug toxicity from coincidence. Ask specifically about homocysteine and folate levels, because these are rarely ordered by default.
Then review the medication list with a pharmacist. Aspirin, other NSAIDs, aminoglycoside antibiotics, and loop diuretics can all add to the problem. A dose reduction of 2.5 to 5 mg weekly is often enough to settle mild tinnitus in low-dose patients, and adding folic acid 1 mg daily is a low-risk step.
Finally, get a baseline audiogram if the ringing persists beyond four weeks. An audiogram costs roughly USD 100 to 300 and provides objective evidence that helps distinguish drug effect from age-related change. If hearing is normal and tinnitus is stable, many patients choose to continue therapy with monitoring rather than switch drugs.
Limitations and What Remains Uncertain
The honest position is that causality is hard to prove in any single patient. Tinnitus is common in the general adult population, affecting 10 to 15 percent at some point, and rheumatoid arthritis patients skew older and often have noise exposure histories. A new ringing ear in a 62-year-old on methotrexate may have nothing to do with the drug.
Most of the evidence is case reports and pharmacovigilance signals rather than randomized trials. No large prospective study has measured audiometric change before and after methotrexate initiation at low dose. The mechanism linking folate antagonism to cochlear dysfunction is biologically plausible but not established in humans.
What is established is the dose-response pattern: higher doses, poorer renal clearance, and absent folate supplementation all raise the odds. That pattern is enough to justify vigilance, a low threshold for blood work, and a trial of folate repletion before assuming the drug must be abandoned. The practical rule is simple: treat new tinnitus on methotrexate as a signal to check levels and kidney function, not as a reason to panic, and not as something to ignore.